{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:51:50Z","timestamp":1782899510043,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019937","name":"Hubei University State Key Laboratory of Biocatalysis and Enzyme Engineering","doi-asserted-by":"publisher","award":["SKLBEE2022007"],"award-info":[{"award-number":["SKLBEE2022007"]}],"id":[{"id":"10.13039\/501100019937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ijbiomac.2024.139403","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:15:47Z","timestamp":1735557347000},"page":"139403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Design of minibinder proteins specific to TNFR1"],"prefix":"10.1016","volume":"293","author":[{"given":"Jun","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banbin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zigong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ijbiomac.2024.139403_bb0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","article-title":"Death by TNF: a road to inflammation","volume":"23","author":"van Loo","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.139403_bb0010","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/jcm12041630","article-title":"Past, present and (foreseeable) future of biological anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.139403_bb0015","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.ijbiomac.2024.139403_bb0020","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2024.139403_bb0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.ijbiomac.2024.139403_bb0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fmed.2019.00014","article-title":"Psoriatic synovitis: singularity and potential clinical implications","volume":"6","author":"Celis","year":"2019","journal-title":"Front. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2024.139403_bb0035","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1177\/0091270007301623","article-title":"The role of TNF\u03b1 in ulcerative colitis","volume":"47","author":"Sands","year":"2007","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.139403_bb0040","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00054725-199811000-00014","article-title":"Infliximab approved for use in Crohn\u2019s disease: a report on the FDA GI advisory committee conference","volume":"4","author":"Kornbluth","year":"1998","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.139403_bb0045","first-page":"5","article-title":"Recombinant DNA product for rheumatoid arthritis","volume":"37","year":"2003","journal-title":"FDA Consum."},{"issue":"2 Suppl","key":"10.1016\/j.ijbiomac.2024.139403_bb0050","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/mjd.2003.554","article-title":"Etanercept: an overview","volume":"49","author":"Goffe","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.139403_bb0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.139403_bb0060","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1212\/WNL.57.10.1885","article-title":"Onset of multiple sclerosis associated with anti-TNF therapy","volume":"57","author":"Sicotte","year":"2001","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ijbiomac.2024.139403_bb0065","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"9306","key":"10.1016\/j.ijbiomac.2024.139403_bb0070","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ijbiomac.2024.139403_bb0075","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri1184","article-title":"Signalling pathways of the TNF superfamily: a double-edged sword","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.139403_bb0080","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0092-8674(93)90132-A","article-title":"Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation","volume":"73","author":"Banner","year":"1993","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.139403_bb0085","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1006\/bcmd.1998.0187","article-title":"TNF, apoptosis and autoimmunity: a common thread?","volume":"24","author":"Beutler","year":"1998","journal-title":"Blood Cells Mol. Dis."},{"issue":"9","key":"10.1016\/j.ijbiomac.2024.139403_bb0090","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41584-023-01002-7","article-title":"TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond","volume":"19","author":"Siegmund","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"issue":"34","key":"10.1016\/j.ijbiomac.2024.139403_bb0095","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1016\/j.biomaterials.2009.08.041","article-title":"The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF","volume":"30","author":"Shibata","year":"2009","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.139403_bb0100","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1074\/jbc.M707933200","article-title":"Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-\u03b1 antagonist*","volume":"283","author":"Shibata","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"28","key":"10.1016\/j.ijbiomac.2024.139403_bb0105","doi-asserted-by":"crossref","first-page":"9379","DOI":"10.1074\/jbc.RA120.012723","article-title":"Structural optimization of a TNFR1-selective antagonistic TNF\u03b1 mutant to create new-modality TNF-regulating biologics","volume":"295","author":"Inoue","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"8016","key":"10.1016\/j.ijbiomac.2024.139403_bb0110","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"issue":"7910","key":"10.1016\/j.ijbiomac.2024.139403_bb0115","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41586-022-04654-9","article-title":"Design of protein-binding proteins from the target structure alone","volume":"605","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2024.139403_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.128666","article-title":"De novo design of a protein binder against Staphylococcus enterotoxin B","volume":"257","author":"Ming","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.139403_bb0125","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jps.22758","article-title":"Developability index: a rapid in silico tool for the screening of antibody aggregation propensity","volume":"101","author":"Lauer","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.139403_bb0130","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/jcc.21366","article-title":"How to obtain statistically converged MM\/GBSA results","volume":"31","author":"Genheden","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ijbiomac.2024.139403_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2021.105857","article-title":"Recombinant expression, purification and characterization of human soluble tumor necrosis factor receptor 2","volume":"182","author":"Li","year":"2021","journal-title":"Protein Expr. Purif."},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2024.139403_bb0140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0022-1759(84)90147-9","article-title":"Comparison of in vitro cell cytotoxic assays for tumor necrosis factor","volume":"68","author":"Flick","year":"1984","journal-title":"J. Immunol. Methods"},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.139403_bb0145","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1006\/cyto.1998.0492","article-title":"Modes of L929 cell death induced by TNF-alpha and other cytotoxic agents","volume":"11","author":"Humphreys","year":"1999","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.ijbiomac.2024.139403_bb0150","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1084\/jem.187.9.1477","article-title":"Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor","volume":"187","author":"Vercammen","year":"1998","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2024.139403_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072156","article-title":"Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity","volume":"8","author":"Richter","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ijbiomac.2024.139403_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705485","article-title":"The TNFR1 antagonist atrosimab is therapeutic in mouse models of acute and chronic inflammation","volume":"12","author":"Richter","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2024.139403_bb0165","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1074\/jbc.M114.617787","article-title":"Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1","volume":"290","author":"Steeland","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.139403_bb0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/cei.12680","article-title":"Specificity of human anti-variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-\u03b1 receptor 1","volume":"182","author":"Cordy","year":"2015","journal-title":"Clin. Exp. Immunol."},{"issue":"16","key":"10.1016\/j.ijbiomac.2024.139403_bb0175","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1016\/j.cell.2024.05.052","article-title":"Preclinical proof of principle for orally delivered Th17 antagonist miniproteins","volume":"187","author":"Berger","year":"2024","journal-title":"Cell"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024102140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024102140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:41:48Z","timestamp":1782898908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813024102140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":35,"alternative-id":["S0141813024102140"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.139403","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of minibinder proteins specific to TNFR1","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.139403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"139403"}}